P
PPH icon

&Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

&Partners’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
12,954
+1,084
+9% +$112K 0.01% 1218
2026
Q1 		$1.23M Buy
11,870
+4,821
+68% +$514K 0.01% 1181
2025
Q4 		$727K Buy
+7,049
New +$686K ﹤0.01% 1414

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

&Partners's PPH Position: Q2 2026 in Review

&Partners increased its VanEck Pharmaceutical ETF (PPH) stake by 9.1% in Q2 2026, buying an estimated $112K and bringing the position to 12,954 shares worth $1.42M. The position accounts for 0.01% of the portfolio, ranked #1218.

&Partners first reported a position in PPH in Q4 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • &Partners held 12,954 shares of VanEck Pharmaceutical ETF worth $1.42M as of Q2 2026.
  • &Partners bought 1,084 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $112K.
  • VanEck Pharmaceutical ETF made up 0.01% of &Partners's portfolio in Q2 2026, its #1218 holding.
  • &Partners first reported a position in VanEck Pharmaceutical ETF in Q4 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.